Tosylphenylalanyl Chloromethyl Ketone (TPCK)

An inhibitor of Serine Endopeptidases. Acts as alkylating agent and is known to interfere with the translation process.

Also Known As:

TPCK; Chloromethane, Tosylphenylalanyl; Chloromethyl Ketone, Tosylphenylalanyl; Ketone, Tosylphenylalanyl Chloromethyl; Chlorophenyltosylamidobutanone; Tosylphenylalanyl Chloromethane; Benzenesulfonamide, N-(3-chloro-2-oxo-1-(phenylmethyl)propyl)-4-methyl-, (S)-

Networked: 53 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Feng, Yangzheng: 3 articles (12/2006 - 11/2002)
2.	LeBlanc, Michael H: 3 articles (12/2006 - 11/2002)
3.	Guo, Jun: 2 articles (03/2010 - 12/2009)
4.	Braga-Silva, Lys A: 1 article (11/2019)
5.	Branquinha, Marta H: 1 article (11/2019)
6.	Cruz, Lucas P S: 1 article (11/2019)
7.	Gandra, Rafael M: 1 article (11/2019)
8.	Gonçalves, Diego S: 1 article (11/2019)
9.	Sangenito, Leandro S: 1 article (11/2019)
10.	Santos, André L S: 1 article (11/2019)

Related Diseases

1.	Brain Injuries (Brain Injury) 01/01/2003 - "Pretreatment with TPCK reduces brain injury. " 03/03/2000 - "We wished to see if TPCK would reduce brain injury in vivo. " 11/01/2002 - "In this experiment TPCK reduces bcl-2 and caspase-3 concentration in animals who have been shown in our previous studies to be protected by TPCK from hypoxic ischemic brain injury. " 03/03/2000 - "TPCK pretreatment in the newborn rat model of hypoxic-ischemic brain injury reduces DNA fragmentation, nitric oxide production and brain injury." 01/01/2003 - "Treatment of hypoxic-ischemic brain injury in newborn rats with TPCK 3 h after hypoxia decreases caspase-9 activation and improves neuropathologic outcome."
2.	Carcinoma (Carcinomatosis) 08/01/2004 - "Multiple effects of N-alpha-tosyl-L-phenylalanyl chloromethyl ketone (TPCK) on apoptotic pathways in human prostatic carcinoma cell lines." 08/01/2004 - "In this study, we show that TPCK inhibits TRAIL-induced caspase activity but potentiates wortmannin-dependent caspase activity in prostatic carcinoma cell lines. "
3.	Neoplasms (Cancer) 08/01/2004 - "Together, these features suggest that TPCK could be used as a therapeutic agent for treatment of those tumor cells that are resistant to ligand-induced treatment because of aberrant signaling pathways downstream of the DISC." 01/01/1997 - "More recently, activation of a N-tosyl-L-phenylalanylchloromethyl ketone (TPCK)-sensitive pathway was also suggested to play an important role in apoptosis induction following cancer chemotherapy. " 01/01/1979 - "The inhibitory effects of TPCK and TLCK seen in transplanted hepatomas and a colon tumor were not generally seen in normal tissues of the tumor-bearing rats." 06/01/2013 - "Two of these inhibitors, PD98059 and TPCK, had anti-tumor activity as single agents in both zebrafish embryonal rhabdomyosarcoma and a human cell line of rhabdomyosarcoma that harbored activated mutations in NRAS. " 01/01/1997 - "The Bcl-xL and Bax-alpha control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation."
4.	Infections 04/01/2008 - "Thus, TPCK prevented the release of HSV-1 DNA into the nucleus when added to medium 1 hour after infection with tsB7 at 39.5 degrees C followed by a shift down to the permissive temperature. " 12/20/1998 - "Neither zVAD.fmk nor TPCK, at the concentrations affecting the apoptotic response, exerted appreciable influence on the virus growth or cellular pathological changes on productive infection, indicating that the pathways leading to the poliovirus-evoked CPE and apoptosis are different." 01/01/2007 - "Moreover, TPCK treatment prior to V. cholerae infection indicated that proinflammatory cytokine gene expression in Int407 cells is NF-kappaB mediated. " 01/01/1987 - "In a normally permissive, fusogenic infection of MHV in L-2 cells, the protease inhibitors TPCK and ZPCK, but not TLCK, were found to inhibit cell fusion. " 04/01/2008 - "(i) Exposure of cells at the time of or before infection to l-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK), a serine-cysteine protease inhibitor, prevents the release of viral DNA or expression of viral genes. "
5.	Sexually Transmitted Diseases (Sexually Transmitted Disease) 12/01/2001 - "The enzyme was 43-fold activated in the presence of 1 mM DTT, insensitive to synthetic inhibitors of serine (PMSF, TLCK, TPCK) and cysteine (IAA, E-64) proteinases, strongly inhibited by STI, and displayed four active bands on zymograms. " 06/01/2000 - "The inhibitors to trypsin, leupeptin antipain and STI also repressed the activity of MAP-21, while chymostatin, TPCK and elastatinal TEI were shown no inhibition to its activity, demonstrating that, MAP-21 was a trypsin-like protease. " 03/01/2015 - "We analyzed four serine protease inhibitors [4-(2-aminoethyl) benzene sulfonyl fluoride hydrochloride (AEBSF), soybean trypsin inhibitor from glycine max (STI), Nα-tosyl-L-lysine-chloromethyl ketone hydrochloride (TLCK) and N(p)-tosyl-L-phenylalanine-chloromethyl ketone (TPCK)] for their in vitro effect on fertilization and sperm quality in pigs. " 01/01/2018 - "Among the common protease inhibitors, phenylmethyl sulfonyl fluorine (PMSF), Nα-p-methyl sulfonyl-L-lysine chloromethylketone (TLCK), Nα-methyl sulfonyl-L- phenylalanine chloromethyl ketone (TPCK), soybean trypsin inhibitor (STI), and PMSF inhibited the total protease, high-alkaline trypsin (a trypsin subtype with highly alkaline pH optimum), low-alkaline trypsin (another trypsin subtype with slightly alkaline pH optimum), and chymotrypsin; TLCK inhibited the total protease and high-alkaline trypsin, whereas TPCK only activated the high-alkaline trypsin activities. "

Related Drugs and Biologics

1.	Caspase 3 (Caspase-3)
2.	Caspases
3.	Wortmannin
4.	Ketones
5.	Tosyllysine Chloromethyl Ketone
6.	Phenylalanine (L-Phenylalanine)
7.	Peptide Hydrolases (Proteases)
8.	Serine Proteinase Inhibitors (Serine Protease Inhibitors)
9.	NF-kappa B (NF-kB)
10.	Protease Inhibitors (Protease Inhibitor)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Drug Therapy (Chemotherapy)